

**KUZYK LAW, LLP**

Michael D. Braun (SBN 167416)  
*mdb@kuzykclassactions.com*  
1999 Avenue of the Stars, Ste. 1100  
Los Angeles, CA 90067  
Telephone: (213) 401-4100  
Facsimile: (213) 401-0311

**KAPLAN FOX & KILSHEIMER LLP**

Laurence D. King (SBN 206423)  
*lking@kaplanfox.com*  
Maia Kats (to be admitted pro hac vice)  
*mkats@kaplanfox.com*  
Mario M. Choi (SBN 243409)  
*mchoi@kaplanfox.com*  
1999 Harrison Street, Suite 1560  
Oakland, CA 94612  
Telephone: (415) 772-4700  
Facsimile: (415) 772-4707

*Counsel for Plaintiff*

**UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA  
SOUTHERN DIVISION**

**JOHN GATTO on behalf of himself  
and all others similarly situated,**

**Plaintiff,**

**v.**

**INTERNATIONAL VITAMIN  
CORPORATION AND NUTRA  
MANUFACTURING, LLC**

**Defendants.**

**CASE NO.: 8:21-cv-889**

**CLASS ACTION**

**COMPLAINT FOR DAMAGES,  
EQUITABLE, DECLARATORY,  
AND INJUNCTIVE RELIEF**

**DEMAND FOR JURY TRIAL**

1 Plaintiff John Gatto (“Plaintiff”), on behalf of himself and all others similarly  
2 situated, brings this class action against International Vitamin Corporation (“IVC”)  
3 and its subsidiary Nutra Manufacturing, LLC (collectively “IVC” or “Defendants”),  
4 and on the basis of personal knowledge, information and belief, and the investigation  
5 of counsel, alleges as follows:

## 6 **INTRODUCTION**

7  
8 1. This is a proposed class action on behalf of a nationwide class and a New  
9 York sub-class of consumers seeking redress for Defendants’ deceptive practices  
10 associated with the advertising, labeling and sale of its Triple Strength Fish Oil sold  
11 under the GNC brand (“Product” or “Supplement”).

12 2. Fish is a major source of healthful long-chain omega-3 fats and are rich  
13 in other nutrients such as vitamin D and selenium, high in protein, and low in  
14 saturated fat. Numerous studies have shown that consuming fatty fish 2-3 times a  
15 week reduces the risk of heart disease and stroke, as well as provides a myriad of  
16 additional health benefits. Scientific consensus is that consuming fatty fish as part of  
17 the diet materially contributes to good health.

18 3. Unfortunately, most Americans do not, or cannot, consume fatty fish  
19 with such regularity and have instead turned to the consumption of fish oil.

20 4. Indeed, as of 2012, fish oil supplements had become the most commonly  
21 used non-vitamin, non-mineral dietary supplement sold in the U.S., and to this day  
22 remain one of the most popular dietary supplement offerings. By 2019, the global fish  
23 oil market was valued at \$1.9 billion, and is currently estimated to reach \$2.8 billion  
24 by 2027. It remains a lucrative business with numerous market participants vying for  
25 consumer attention and their spending dollars.

26 5. Defendants manufacture, label and sell a Product which they claim to be  
27 Triple Strength Fish Oil containing of 734 mg of Eicosapentaenoic Acid (“EPA”) and  
28

266 mg of Docosahexaenoic Acid (“DHA”) – the essential omega-3 fatty acids that naturally occur in fish.



6. Contrary to what is represented on the label, however, this Product is not fish oil, nor does it contain a single milligram of EPA or DHA. What was once natural fish oil has been subjected to a chemical process by which its molecular structure and constituent parts have been substantially transformed and irrevocably altered into a synthesized product that does not otherwise exist in fish, or nature. Through a chemical process known as trans-esterification, an industrial solvent is introduced into the fish oil in order to break its natural triglyceride bonds and cleave the glycerol backbone from fatty acid molecules. Thereafter, ethanol is introduced to which the free fatty acids bond and form fatty acid ethyl esters. Fish oil is stripped of hundreds of its constituent sub ingredients, and the Omega-3s, which include DHA and EPA, are converted into ethyl esters. Critically, these newly formed Omega-3s are different

1 molecules than the Omerga-3s which exist naturally in fish oil. The new chemical by-  
2 products are universally recognized by their common or usual name -- Omega-3 Fatty  
3 Acid Ethyl Esters.

4 7. The most material representation on a dietary supplement label is the  
5 product name – the fundamental indicia of its contents. Once trans-esterified, fish oil  
6 is irrevocably transformed, such that it is no longer fish oil and therefore cannot be so  
7 named or labeled. To do so, as IVC has done, is false, misleading, deceptive,  
8 unlawful, and perpetrates an actionable fraud on the consuming public.

9 8. As alleged herein, Defendants' conduct is in breach of warranty, violates  
10 California's Business and Professions Code § 17200, *et. seq.*, California's Business &  
11 Professions Code § 17500, *et. seq.*, California Civil Code § 1750, *et seq.*, N.Y. Gen.  
12 Bus. Law § 349 *et seq.*, N.Y. Gen. Bus. Law § 350 *et seq.*, and is otherwise grounds  
13 for restitution on the basis of quasi-contract/unjust enrichment.

14 9. Throughout the applicable class periods, Defendants falsely represented  
15 the fundamental nature of their Product, and as a result of this false and misleading  
16 labeling, were able to sell these Products to tens of thousands of unsuspecting  
17 consumers throughout New York and the United States.

#### 18 **JURISDICTION AND VENUE**

19 10. Jurisdiction of this Court is proper under 28 U.S.C. § 1332(d)(2).  
20 Diversity jurisdiction exists as Plaintiff Gatto is a resident of Massapequa, New York  
21 and Defendant IVC is incorporated in Delaware and maintains its principal place of  
22 business in Irvine, California. The amount in controversy exceeds \$5,000,000 for the  
23 Plaintiff and members of the Class collectively, exclusive of interest and costs, by  
24 virtue of the combined purchase prices paid by Plaintiff and members of the putative  
25 Class, and the profits reaped by Defendants from their transactions with Plaintiff and  
26 the Class, as a direct and proximate result of the wrongful conduct alleged herein, and  
27 by virtue of the injunctive and equitable relief sought.  
28



21. Defendant IVC is a Delaware corporation, headquartered in Irvine, California. IVC manufactures and/or supplies various dietary supplements as private label and store brand products to retailers nationwide.<sup>2</sup>

22. On March 1, 2019, non-party GNC entered into an agreement with IVC to sell Nutra to IVC through a series of transactions. See GNC Holdings, Inc., Form 8-K, filed with the United States Securities and Exchange Commission on March 7, 2019 (“Form 8-K”).<sup>3</sup> At the time of the transaction, IVC took a majority 57.14% stake in Nutra with the parties’ expectation that IVC would subsequently purchase the remainder over the next few years.

23. The Supply Agreement between Nutra and a subsidiary of non-party GNC entered on March 1, 2019 confirmed that Nutra would supply non-party GNC’s private label products and would be responsible for, among other things, that all raw materials meet the required manufacturing specifications which include testing, quality control and labeling of the final products consistent with current Good Manufacturing Practices.<sup>4</sup> The Agreement further confirms that Nutra is controlled by IVC, which was and remains headquartered in Irvine, California.

## **GENERAL ALLEGATIONS**

### **A. OMEGA-3 FATTY ACIDS**

24. Omega-3 Fatty Acids (“Omega-3” or “OM3”) are polyunsaturated carboxylic acids that provide numerous health benefits to the human body including a

<sup>2</sup> See, <https://ivcinc.com/what-we-do/> (last visited April 12, 2021)

<sup>3</sup> <https://www.sec.gov/Archives/edgar/data/0001502034/000119312519066485/d631916d8k.htm>.

<sup>4</sup> Product Supply Agreement, Exhibit 10.3, Form 8-K available at <https://www.sec.gov/Archives/edgar/data/1502034/000119312519066485/d631916dex101.htm>.



1 variety of critical organs and systems (e.g., heart, brain, eyes, blood vessels, lungs,  
2 immune, endocrine, and reproductive systems).<sup>5</sup>

3 25. Among the 11 types of OM3s, the three most important to human  
4 physiology are alpha-linolenic acid (“ALA”), docosahexaenoic acid (“DHA”) and  
5 eicosapentaenoic acid (“EPA”).<sup>6</sup>

6 26. ALA Omega-3 fatty acids are primarily found in plant oils and generally  
7 used by the human body for energy. To be used for something other than energy, ALA  
8 must first be converted into EPA or DHA. Unfortunately, this conversion process is  
9 inefficient and results in only a small percentage of ALA being converted into EPA  
10 and DHA.

11 27. In contrast, the primary source of EPA and DHA are marine oils from  
12 fatty fish and other seafoods.

13 28. Although experts have not established a daily recommended amount for  
14 DHA and EPA, the National Institutes of Health, Office of Dietary Supplements  
15 (“NIH”) acknowledges that many scientific studies show that eating fatty fish rich in  
16 DHA and EPA has beneficial effects with respect to a variety of adverse health  
17 conditions such as cardiovascular disease, age-related macular degeneration,  
18 Alzheimer’s disease, dementia, dwindling cognitive function, rheumatoid arthritis,  
19  
20  
21

---

22 <sup>5</sup> *Omega-3 Fatty Acids*, National Institutes of Health, Office of Dietary Supplements, available at  
23 <https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer>; H. Breivik, *Long-chain Omega-3*  
24 *Specialty Oils*, Woodhead Publishing in Food Science, Technology and Nutrition at 11 (hereinafter  
25 “Breivik at \_\_\_”)(Clinical research has suggested that Omega-3s help prevent cardiovascular  
26 disease, Alzheimer’s, dementia, macular degeneration, and rheumatoid arthritis. There is also  
support that Omega-3s provide benefits for sufferers of arthritis, Crohn’s disease and patients with  
neuropsychiatric disorders such as depression and schizophrenia).

27 <sup>6</sup> Other Omega-3s include: hexadecatrienoic acid (HTA); stearidonic acid (SDA); eicosatrienoic acid  
28 (ETE); eicosatetraenoic acid (ETA); heneicosapentaenoic acid (HPA); docosapentaenoic acid  
(DPA); tetracosapentaenoic acid; and tetracosahexaenoic acid.

1 high blood pressure, and variety of other conditions including, potentially, certain  
2 cancers.<sup>7</sup>

3 29. Between 2017 and 2019, the American Heart Association (“AHA”) released three science advisories related to Omega-3s, all of which recommend adults  
4 consume one to two servings of seafood per week to reduce the risk of congestive  
5 heart failure, coronary artery disease, stroke, and sudden cardiac death. For people  
6 with existing coronary artery disease, the AHA recommends approximately 1g/day of  
7 EPA plus DHA, preferably from oily fish.<sup>8</sup>

9 30. In 2019 the U.S. Food and Drug Administration (“FDA”) considered the weight of scientific evidence on the impact of OM3 and approved five qualified health  
10 claims relating to the consumption of the EPA/DHA and its effect on heart health.<sup>9</sup>

12 31. Unfortunately, Americans generally do not consume a sufficient amount  
13 of fatty fish necessary to maintain adequate levels of EPA and DHA. In response to  
14 this deficiency, health care professionals began recommending that Americans  
15 supplement their diets with fish oil.<sup>10</sup>

17  
18 <sup>7</sup> Available at <https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer/>

19 <sup>8</sup> Etherton, P., et al, *Omega-3 Fatty Acids and Cardiovascular Disease New Recommendations From the American Heart Association*, AHA Arteriosclerosis, Thrombosis, and Vascular Biology Journal (2003) available at <https://www.ahajournals.org/doi/full/10.1161/01.ATV.0000057393.97337.AE>;  
20 See also, National Institutes of Health, *Omega-3 Fatty Acids*, available at  
21 <https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/#:~:text=For%20people%20with%20existing%20coronary,of%20a%20physician%20%5B80%5D>.

23 <sup>9</sup> *FDA Announces New Qualified Health Claims for EPA and DHA Omega-3 Consumption and the Risk of Hypertension and Coronary Heart Disease*, June 19, 2019, available at  
24 <https://www.fda.gov/food/cfsan-constituent-updates/fda-announces-new-qualified-health-claims-epa-and-dha-omega-3-consumption-and-risk-hypertension-and>.  
25

26 <sup>10</sup> Mackay, *A Comparison of Synthetic Ethyl Ester Form Fish Oil vs. Natural Triglyceride Form*, available from  
27 <http://www.promedics.ca/site/downloads/Triglycerides%20vs%20Ethyl%20Esters.pdf>.  
28



32. In 1995, fish oil supplements generated only \$35 million in annual sales. By 2005, that number had increased to \$310 million and by 2012, fish oil supplements had become the non-vitamin/non-mineral natural product most commonly taken by both adults and children with approximately 7.8 percent of adults (18.8 million) and 1.1 percent of children age 4 to 17 (664,000) regularly consuming fish oil supplements.<sup>11</sup> By 2019, the global fish oil market had grown to \$1.9 billion, and is currently estimated to reach \$2.8 billion by 2027.<sup>12</sup>

## B. FISH OIL

33. Omega-3 fatty acids, including EPA and DHA, are found in a variety of fatty fish such menhaden, sardines, anchovies, salmon and tuna.<sup>13</sup> The oil from these fish is extracted by a fairly straightforward process which has been employed in a similar fashion since the early 1800s whereby fish were caught, cooked and a rock weighted process was used to press oil from the fish. By the 1850s, the rock weighted process was replaced with a hydraulic press.<sup>14</sup>

34. Today, the process remains relatively the same. Once fish are caught, they are on-boarded to a fishing vessel and quickly boiled. The fish are cooked and


<sup>11</sup> NIH, *Omega-3 Supplements: In Depth*, National Center for Complementary and Integrative Health, available at <https://www.nccih.nih.gov/health/omega3-supplements-in-depth#:~:text=Use%20of%20Omega%2D3%20Supplements%20in%20the%20United%20States&text=The%20survey%20findings%20indicated%20that,in%20the%20previous%2030%20days>.

<sup>12</sup> Global Fish Oil Market (2020 to 2027) - Opportunity Analysis and Industry Forecast - ResearchAndMarkets.com, Business Wire, available at [https://www.businesswire.com/news/home/20200909005847/en/Global-Fish-Oil-Market-2020-to-2027---Opportunity-Analysis-and-Industry-Forecast---ResearchAndMarkets.com#:~:text=The%20global%20fish%20oil%20market,and%20docosahexaenoic%20acids%20\(DHA\)](https://www.businesswire.com/news/home/20200909005847/en/Global-Fish-Oil-Market-2020-to-2027---Opportunity-Analysis-and-Industry-Forecast---ResearchAndMarkets.com#:~:text=The%20global%20fish%20oil%20market,and%20docosahexaenoic%20acids%20(DHA)).

<sup>13</sup> Hossain, M.A., *Fish as Source of Polyunsaturated Fatty Acids (PUFAs), Which One is Better-Farmed or Wild?*, *Advance Journal of Food Science and Technology* 3(6): 455, 459 (Table 2), 2011 (“Hossain Publication”).

<sup>14</sup> Breivik at 28.

pressed, separating the water and oil from proteins and solids. Thereafter, the water is separated from the oil. The oil undergoes a polishing process (i.e., deacidifying, degumming, and washing the oil several times). It is subsequently bleached and deodorized. The resulting oil is ultimately encapsulated and sold as supplements. Below, a diagram representing the standard method for processing fish oil.<sup>15</sup>



35. Most significantly, common fish oil is *derived using a physical, rather than a chemical process*, such that no chemical bonds are broken or created during

<sup>15</sup> Bimbo, A. (2011). *Marine oils; edible oil processing*. AOCS Lipid Library, December 2016, available at <https://lipidlibrary.aocs.org/edible-oil-processing/marine-oils>. The graph represents the wet reduction process -- the most common method used to convert raw fish into fish oil.

1 the extraction, bleaching or deodorizing process. “Fish oil is produced without solvent  
2 extraction [but rather] is pressed out of the cooked fish.”<sup>16</sup>

3 36. The Omega-3 fatty acids in fish oil occur naturally in triglyceride form  
4 (“TAG”). Triglyceride is the term used to define the molecular structure which bond  
5 these fatty acids (i.e., EPA and DHA) to a glycerol backbone. Triglycerides are the  
6 natural molecular form that make up virtually all fats and oils in both animals and  
7 plants and which the human body can directly digest.<sup>17</sup>

8 37. Depending on the type of fish from which oil was derived, and the  
9 environmental conditions in which that fish was raised, the ratio of EPA and DHA can  
10 differ slightly, but typically will account for 30% of the fatty acid content (i.e., 180 mg  
11 of EPA and 120 mg of DHA per 1000 milligrams of oil).<sup>18</sup> Standard fish oil is often  
12 referred to as “18:12,” representing the typical ratio of EPA to DHA by weight (18%  
13 of the oil by weight is EPA; and 12% of the oil by weight is DHA). The remaining  
14 70% of the fish oil consists of saturated fats, other omega-3 fatty acids, omega-6 and  
15 omega-9 fatty acids.<sup>19</sup>

---

16  
17  
18  
19  
20 <sup>16</sup> Breivik at 25.

21 <sup>17</sup> See, e.g., Omega3 of Norway, available at [https://norwayomega.com/omega3-fish-oil/#natural-](https://norwayomega.com/omega3-fish-oil/#natural-triglycerides-vs-artificial-ethylesters)  
22 [triglycerides-vs-artificial-ethylesters](https://norwayomega.com/omega3-fish-oil/#natural-triglycerides-vs-artificial-ethylesters) (last visited April 14, 2021).

23 <sup>18</sup> NIH, *Omega-3 Fatty Acids, Fact Sheet for Health Professionals*, National Institutes of Health,  
24 *Office of Dietary Supplements* (“NIH Fact Sheet”) available at  
<https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional>.

25 <sup>19</sup> Lembke, P., *Production Techniques for Omega-3 Concentrates*, Omega-6/3 Fatty Acids:  
26 Functions, sustainability Strategy and Perspectives, DOI 10.1007/978-1-62703-215-5 (2013)  
27 available at [https://www.puroomega.com/wp-content/uploads/2016/06/Lembke-2013-Production-](https://www.puroomega.com/wp-content/uploads/2016/06/Lembke-2013-Production-Techniques-Omega-3-Human-Press-2013-pp353-364.pdf)  
28 [Techniques-Omega-3-Human-Press-2013-pp353-364.pdf](https://www.puroomega.com/wp-content/uploads/2016/06/Lembke-2013-Production-Techniques-Omega-3-Human-Press-2013-pp353-364.pdf) (last visited April 14, 2021).

## C. OMEGA-3 FATTY ACID ETHYL ESTERS

38. In the early 1980's, the Japanese pharmaceutical company Mochida developed a large-scale method to synthesize EPA and DHA into an ethyl ester chemical form. The process, known as trans-esterification, enabled scientists to increase the yield of omega-3s from 30% to upwards of 70% as well as manipulate the ratio between EPA and DHA.<sup>20</sup> It also allowed chemists to use lower grade fish oil as the starting material as rancidity due to age, storage and processing of the oil are removed in the trans-esterification process.

39. Doing so, however, required the chemical alteration of fish oil on a molecular level, substantially transforming it from a natural product, into a synthetic product called Omega-3 Fatty Acid Ethyl Esters – a substance that is not found anywhere in nature, and which has not been comparably viewed by leading health authorities.

40. Importantly, trans-esterification begins only after fish has been processed into oil.<sup>21</sup> At that juncture, manufacturers have a choice – to sell fish oil as it is, or engage in the trans-esterification process as a means to boosting profits.

### (1) *The Trans-Esterification Process*

41. The first step in the trans-esterification process involves a chemical reaction whereby the glycerol backbone of each triglyceride molecule in the fish oil is broken by introduction of an industrial chemical such as sodium hydroxide, resulting in free fatty acids and a free glycerol molecule.<sup>22</sup> The free fatty acid forms of EPA and

---

<sup>20</sup> Klinik, M., *A Review of Omega-3 Ethyl Esters for Cardiovascular Prevention and Treatment of Increased Blood Triglyceride Levels*, Vasc Health Risk Manag (2006), doi: 10.2147/vhrm.2006.2.3.251.

<sup>21</sup> Breivik at 25.

<sup>22</sup> Douglas MacKay, ND, *A Comparison of Synthetic Ethyl Ester Form Fish Oil vs. Natural Triglyceride Form* ("MacKay Publication"), [http://www.healthwiseonline.com/pdf/stuart\\_tomc\\_nordic\\_naturals\\_tg\\_vs\\_ee.pdf](http://www.healthwiseonline.com/pdf/stuart_tomc_nordic_naturals_tg_vs_ee.pdf); Bimbo, A, *Marin*

1 DHA, which are inherently unstable, are chemically reacted with ethanol (an  
 2 industrial alcohol).<sup>23</sup> In a subsequent process known as molecular distillation, the  
 3 mixture is heat distilled under a vacuum resulting in a condensate omega-3 ethyl ester  
 4 solution.<sup>24</sup> The concentration of omega-3s in the solution depends on variables within  
 5 the distillation process, but typically ranges from 50-70%.<sup>2</sup> The constituent  
 6 compounds are DHA Ethyl Esters and EPA Ethyl Esters — which are molecularly  
 7 distinct from the precursor DHA and EPA triglyceride (“TAG”) molecules. The  
 8 diagram below shows the most common trans-esterification process beginning with  
 9 crude fish oil and resulting in the formation of ethyl esters.<sup>25</sup>

10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18 


---

Oils, AOCS Lipid Library, available at [https://lipidlibrary.aocs.org/edible-oil-processing/marine-](https://lipidlibrary.aocs.org/edible-oil-processing/marine-oils)  
 19 oils.

20 <sup>23</sup> See MacKay Publication; see also *Triglycerides vs. Ethyl Ester Forms of Fish Oil*, Science Based  
 21 Health, [https://www.sciencebasedhealth.com/Fish-Oil-EE-vs-TG-omega-3s-which-is-better-](https://www.sciencebasedhealth.com/Fish-Oil-EE-vs-TG-omega-3s-which-is-better-W119.aspx)  
 22 [W119.aspx](https://www.sciencebasedhealth.com/Fish-Oil-EE-vs-TG-omega-3s-which-is-better-W119.aspx).

23 <sup>24</sup> Molecular distillation is a type of short-path vacuum distillation, characterized by an extremely  
 24 low vacuum pressure which is performed using a molecular still. This process is characterized by  
 25 short term exposure of the distillate liquid to high temperatures in high vacuum in the distillation  
 26 column and a small distance between the evaporator and the condenser.  
 27 [https://en.wikipedia.org/wiki/Molecular\\_distillation](https://en.wikipedia.org/wiki/Molecular_distillation); See also Breivik, H., H. G.G., and B.  
 28 Kristinsson, *Preparation of highly purified concentrates of eicosapentaenoic acid and*  
*docosahexaenoic acid*, JAOCS, 1997. 74(11): p. 1425-29; Breivik, H. *Concentrates. In: Long Chain*  
*Omega-3 Specialty Oils*, pp. 111-140, The Oily Press Bridgwater England (2007).

<sup>25</sup> Bimbo, A.P. *Processing of marine oils. In: Long Chain Omega-3 Specialty Oils*, pp. 77-109 (H.  
 Breivik (ed.) The Oily Press Bridgwater England) (2007).



42. The trans-esterification process allows manufacturers to do one of several things that yield significant financial benefits: (1) Increase the levels of EPA-EE and DHA-EE far in excess of the 18/12 limit of TAG EPA and TAG DHA in fish oil. Where the standard fish oil yields only 30% DHA/EPA by volume, trans-esterification allows manufacturers to obtain DHA-EE and EPA-EE that yields upwards of 70% by volume; (2) Alter the natural ratios of DHA/EPA (i.e., 120 mg / 180 mg per 1000 mg) to create DHA-EE / EPA-EE in any ratio the manufacturer desires; (3) Use low grade crude fish oil generated from fish offal -- heads, viscera and other body parts discarded in preparing fish for consumption (i.e. fish waste) -- in lieu of a whole small oily fish (e.g., sardine, anchovy, menhaden) that are traditionally caught and processed for the production of fish oil. In addition to being low quality, offal produces small volumes of oil compared to whole fish because these edible species are primarily non-fatty fish.<sup>26</sup> For example, a study exploring the efficiency of extracting oil from the heads of two tuna species, found the crude oil yields are only between 1-2%, far less than the average 30% yield from whole fish species that are caught specifically for

<sup>26</sup> Bimbo, A. (2011). Marine oils; edible oil processing. AOCS Lipid Library, December 2016, available at <http://lipidlibrary.aocs.org/OilsFats/content.cfm?ItemNumber=40332>



rendering of fish oil.<sup>27</sup> Inconsistent and low yields, in addition to the fact that the raw materials consist of fish waste renders the resulting crude fish oil unsuitable for human consumption and requires trans-esterification to create a useable yield.<sup>28</sup>

43. At the end of the trans-esterification process, the crude fish oil has been substantially transformed into Fatty Acid Ethyl Esters consisting of DHA-EE, EPA-EE and other OM3 fatty acid ethyl esters. At this point, the solution may be encapsulated and sold as a dietary supplement, or further concentrated, refined and sold as a drug.<sup>29</sup>

44. Ultimately, once trans-esterified, fish oil is substantially and irrevocably transformed into Omega-3 fatty acid ethyl esters -- a substance that cannot be found in any part of any fish. Calling it "fish oil," therefore, is fraudulent, deceptive and misleading.

#### **D. OMEGA-3 FATTY ACID ETHYL ESTERS ARE NOT FISH OIL**

##### **(1) *DHA & EPA Ethyl Esters are Different Molecules than DHA & EPA Found in Natural Fish Oil***

45. The trans-esterification process substantially and irrevocably transforms the Omega-3s in fish oil from their natural triglyceride form into Omega-3 fatty acid ethyl esters. Critically, these substances, (fish oil and omega-3 fatty acid ethyl esters), are distinguishable on a molecular level such that it is impossible as a matter of law or logic for them to share a common or usual name. Indeed, they do not. Along with

<sup>27</sup> Kasmiran, B. 2018. Comparison and evaluation of the quality of fish oil and fishmeal extracted from the heads of Yellowfin tuna (*Thunnus albacares*) and Albacore tuna (*Thunnus alalunga*). Nations University Fisheries Training Programme, Iceland, available at <http://www.unuftp.is/static/fellows/document/britney16prf.pdf>.



<sup>28</sup> Alfio, V, et al, *From Fish Waste to Value: An Overview of the Sustainable Recovery of Omega-3 for Food Supplements*, *Molecules*. 2021 Feb; 26(4): 1002. Published online 2021 Feb 13. doi: 10.3390/molecules26041002 available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918619/>

<sup>29</sup> See e.g., Lovaza Prescribing information available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/021654s023lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021654s023lbl.pdf).

their molecular differences, they have different common or usual names which must be properly represented on labeling of any dietary supplement in which they are contained. To do otherwise is deceptive, misleading, fraudulent and illegal.

	DHA <sup>30</sup>	DHA-EE <sup>31</sup>
<b>Empirical Formulae</b>	<b>C<sub>22</sub>H<sub>32</sub>O<sub>2</sub></b>	<b>C<sub>24</sub>H<sub>36</sub>O<sub>2</sub></b>
<b>Molecular Weight</b>	328.50 g/mol	356.55 g/mol
<b>Synonyms</b>	Docosahexaenoic acid Doconexent, Cervonic acid, Doconexento Doconexentum Doxonexent Docosahexaenoate	Docosahexaenoic acid ethyl ester Ethyl docosahexaenoate Cervonic acid ethyl ester

#### Molecular Structures





<sup>30</sup> See NIH, National Library of Medicine available at <https://pubchem.ncbi.nlm.nih.gov/compound/445580>

<sup>31</sup> See NIH, National Library of Medicine available at <https://pubchem.ncbi.nlm.nih.gov/compound/9831416>

	EPA <sup>32</sup>	EPA-EE <sup>33</sup>
<b>Empirical Formulae</b>	<b>C<sub>20</sub>H<sub>30</sub>O<sub>2</sub></b>	<b>C<sub>22</sub>H<sub>34</sub>O<sub>2</sub></b>
<b>Molecular Weight</b>	302.5 g/mol	330.51
<b>Synonyms</b>	Eicosapentaenoic acid Icosapent, 10417-94-4 Icosapento Icosapentum Timnodonic acid	Eicosapentaenoic acid ethyl ester Epadel Ethyl eicosapentaenoate Ethyl eicosapentaenoic acid Ethyl icosapentaenoate Ethyl icosapentate Ethyl-eicosapentaenoic acid Ethyl-EPA Icosapentaenoate icosapentate Icosapent ethyl Timnodonic acid ethyl ester

#### Molecular Structures



<sup>32</sup> Pub Chem, available at <https://pubchem.ncbi.nlm.nih.gov/compound/446284>

<sup>33</sup> Pub Chem, available at <https://pubchem.ncbi.nlm.nih.gov/compound/9831415>

1           46. As demonstrated above, these molecules are distinct in every regard.  
2 They have different molecular weights, chemical structures, physical properties and  
3 common/usual names.

## 4                                   (2) Monographs

5           47. The United States Pharmacopeia (“USP”) is one of the most  
6 comprehensive sources for medicine and dietary supplement standards in the world.  
7 The USP National Formulary (“USP-NF”) provides over 5000 reference standards for  
8 medicines and over 300 reference standards for dietary supplements. The standards  
9 are used to help ensure the quality of these products and their ingredients, and to  
10 protect the safety of patients.<sup>34</sup>

11           48. Among its quality standards, the USP-NF provides a series of  
12 monographs which articulate the quality expectations for “identity, strength, purity,  
13 and performance” of certain drugs and dietary supplements. *Id.* Included among the  
14 USP references for dietary substances are monographs for Docosahexaenoic Acid  
15 Ethyl Ester (500 mg); Docosahexaenoic Acid (250 mg); Eicosapentaenoic Acid (300  
16 mg); Eicosapentaenoic Acid Ethyl Ester; Fish Oil Omega-3 Acid Ethyl Esters  
17 Concentrate; Omega-3-Acid Ethyl Esters; and Fish Oil (1 g).

18           49. Figure A below juxtaposes the mass spectra of the USP monograph for  
19 fish oil with that of IVC’s Triple Strength Fish Oil.<sup>35</sup> As demonstrated below, fish oil  
20 is an amazingly complex natural product which consists of hundreds of constituent  
21 ingredients. In contrast, the IVC Product is a synthetic construct consisting primarily  
22 of DHA-EE and EPA-EE. Each peak represents a different molecule with a unique  
23 mass to charge ratio (m/z). From a macro perspective, the monographs undeniably  
24

---

25 <sup>34</sup> <https://www.usp.org/about/public-policy/overview-of-monographs>

26 <sup>35</sup> United States Pharmacopeia – National Formulary Catalog # 1270424, available at  
27 [https://store.usp.org/OA\\_HTML/ibeCCtpItmDspRte.jsp?sitex=10020:22372:US&item=33515](https://store.usp.org/OA_HTML/ibeCCtpItmDspRte.jsp?sitex=10020:22372:US&item=33515)  
28

demonstrate that these are distinct products. From a granular perspective, the monographs highlight the fact that, despite their representation to the contrary, the IVC Product contains no DHA or EPA, much less in the amounts claimed.




Figure A: Comparison of USP fish oil standard with IVC's Triple Strength Fish Oil.

50. In addition to the USP, numerous industry and scientific authorities independently confirm the differences between fish oil and omega-3 fatty acid ethyl esters.

51. Codex Alimentarius Commission ("Codex") was created in 1963 by two U.N. organizations, the Food and Agriculture Organization and the World Health Organization. Its main purpose is to protect the health of consumers and to ensure fair practices in international trade in food through the development of food standards, codes of practice, guidelines and other recommendations. Codex standards and

1 guidelines are developed by committees, which are open to all member countries.  
 2 Member countries review and provide comments on Codex standards and related texts  
 3 at several stages in the development process. In the United States, public meetings are  
 4 held to receive comments on Codex drafts and comments are invited from all  
 5 interested parties. Although Codex standards and related texts are voluntary, they do  
 6 provide a template for laws and are used by the World Trade Organization as an  
 7 agreed benchmark in global trade disputes.<sup>36</sup>

8 52. FDA participates and exercises leadership in the Codex Alimentarius  
 9 Commission. The objective of FDA's participation in Codex is to develop science-  
 10 based international food safety, labeling, and other pertinent standards that provide  
 11 consumer protection, labeling information, and prevention of economic fraud and  
 12 deception that are consistent with U.S. regulations and laws.

13 53. FDA uses procedures that promote consumer protection and  
 14 transparency, as it works with the U.S. Codex Office to develop U.S. Delegation  
 15 positions on matters before relevant Codex committees.<sup>37</sup>

16 54. In 2017, the Codex Alimentarius Committee adopted standards for fish  
 17 oil. It was a long process that started in 2011 "involving many discussions on the finer  
 18 details which was important to clarify as the purpose of this Standard is to protect  
 19 consumer health and promote fair practices in the trade of fish oil."<sup>38</sup> Significantly,  
 20  
 21

---

22 <sup>36</sup> FDA, *Responses to Questions about Codex and Dietary Supplements*, available  
 23 [https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-](https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/responses-questions-about-codex-and-dietary-supplements#what)  
 24 [information/responses-questions-about-codex-and-dietary-supplements#what](https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/responses-questions-about-codex-and-dietary-supplements#what) (last visited April 13, 2021).

25 <sup>37</sup> FDA, *FDA's Participation in Codex*, available at [https://www.fda.gov/food/international-](https://www.fda.gov/food/international-cooperation-food-safety/fdas-participation-codex)  
 26 [cooperation-food-safety/fdas-participation-codex](https://www.fda.gov/food/international-cooperation-food-safety/fdas-participation-codex) (last visited April 13, 2021).

27 <sup>38</sup> IFFO, *CODEX Standard for Fish Oil*, available at <https://www.iffonet.net/codex-standard-fish-oil>  
 28 (last visited April 13, 2021).



1 the Codex, like the USP, recognizes and draws a distinction between natural fish oil  
2 and trans-esterified products.<sup>39</sup>

3 55. Similarly, the Global Organization for EPA and DHA omega-3s  
4 (“GOED”), the largest and most significant trade group of the Omega-3 industry, also  
5 maintains a series of monographs which, like the USP and CODEX, differentiate  
6 between TAG, EE and rTG Omega-3s as well a series of particular fish oils (e.g.,  
7 Salmon, Tuna, Anchovy, etc). It provides members “technical guidance on specific  
8 and recommended test methodologies and quality parameters for a number of EPA  
9 and/or DHA containing product classes currently covered under the GOED Voluntary  
10 Monograph.”<sup>40</sup> EPA/DHA-containing product classes currently covered by this  
11 GOED Voluntary Monograph [include]: Refined EPA and/or DHA Omega-3 Oil  
12 Triglycerides, EPA and/or DHA Omega-3 Oil Ethyl Ester Concentrates, EPA and/or  
13 DHA Omega-3 Oil Triglyceride Concentrates, Tuna Oil, Salmon Oil and Anchovy  
14 Oil. Consistent with the USP and Codex, GOED’s monographs confirm that fish oil is  
15 not synonymous with fatty acid ethyl esters and cannot be so named.

### 16 (3) U.S. Customs and Border Protection

17 56. The U.S. Customs and Border Protection (“CBP”) is one of the world's  
18 largest law enforcement organizations whose duties include the facilitation of lawful  
19 international trade.<sup>41</sup> Among other things, the CPB is responsible for the interpretation  
20

21 <sup>39</sup> Section 2.2 defines “Fish oils” as those derived from one or more species of fish or shellfish.<sup>39</sup> In  
22 contrast, Section 2.6 defines “Concentrated fish oils ethyl esters” as those derived from fish oils  
23 described in Section 2.1 to 2.4 and are primarily composed of fatty acids ethyl esters. See, *Report of*  
24 *the U.S. Delegate, 25th Session, Codex Committee on Fats and Oils, United States Department of*  
*Agriculture*, available at <https://www.usda.gov/sites/default/files/documents/delegates-report-02272017.pdf> (last visited April 13, 2021).

25  
26 <sup>40</sup> GOED Voluntary Monograph, Version 7.2, March 15, 2021 , available at  
27 <https://goedomega3.com/goed-monograph> (last visited April 13, 2021).

28 <sup>41</sup> See, U.S. Customs and Border Protection available at <https://www.cbp.gov/about> (last visited April 13, 2021).

1 and enforcement of the Harmonized Tariff Schedule of the United States (“HTS”)  
 2 which is a hierarchical structure for describing all goods in trade for duty, quota, and  
 3 statistical purposes.<sup>42</sup>

4 57. The CPB has issued more than 20,000 rulings related to the proper  
 5 interpretation of products and where they may be classified under the HTS.

6 58. On several occasions the CPB considered the appropriate tariff  
 7 classification for Omega-3 Acid Ethyl Esters. Consistently, the CPB recognized that  
 8 trans-esterification substantially transforms fish oil into a different product which  
 9 results in a different tariff classification.

10 59. In 2011, the CPB tested and reviewed a product that was described as “a  
 11 gelatin capsule containing 1000 milligrams of fish oil, said to be derived from  
 12 anchovy, sardine, herring or other fish species.” The CPB determined that the “fish  
 13 oil” had been substantially transformed from its original fish oil source -- “the crude  
 14 fish oil has been refined and chemically modified by deodorizing, ethylating  
 15 (conversion of triglycerides to ethyl esters), distillation, winterizing/cold filtrating,  
 16 bleaching and drumming.” Accordingly, while the petitioner sought to classify the  
 17 trans esterified product under Section 1504.20.4000 of the HTS which pertains to  
 18 “fish-liver oils and their fractions, whether or not refined, *but not chemically*  
 19 *modified*,” the CPB concluded that “[b]ased on the manufacturing process of the fish  
 20 oil, they will be classified elsewhere.... The applicable subheading for these products  
 21 will be 2106.90.9998, HTSUS, which provides for food preparations not elsewhere  
 22 specified or included...other...other...other. The duty rate will be 6.4 percent ad  
 23 valorem.” (emphasis added).<sup>43</sup>

24  
 25  
 26 <sup>42</sup> United States International Trade Commission, available at  
[https://www.usitc.gov/harmonized\\_tariff\\_information](https://www.usitc.gov/harmonized_tariff_information) (last visited April 13, 2021).

27  
 28 <sup>43</sup> Customs Ruling, N171795, July 5, 2011, available at  
<https://rulings.cbp.gov/search?term=N171795&collection=ALL&sortBy=RELEVANCE&pageSize>

60. Just as an apple cannot be called a pear, an omega-3 acid ethyl ester cannot be called fish oil. As the industry’s “leading manufacturer of vitamin and nutritional supplements [and the] #1 private label manufacturer in the United States,” IVC is obligated by law to label its Products truthfully and accurately. At bottom, this Product is a fatty acid ethyl ester. Labeling and selling it as fish oil is false, misleading, deceptive and unlawful.

### **SPECIFIC LABELING VIOLATIONS**

61. The Federal Food, Drug & Cosmetic Act (“FDCA”) broadly regulates the sale of food and beverages to the consuming public. 21 U.S.C §301. It was promulgated in significant part to prevent consumer deception and was principally implemented through the creation of a uniform system of labeling on which consumers could rely to make informed purchasing decisions.

62. The FDCA prohibits the misbranding of any food. 21 U.S.C. §331(b). Generally, a food is misbranded if, among other things, its labeling is false or misleading. 21 U.S.C. § 343.

63. The Nutrition Labeling and Education Act of 1990 amended the FDCA by requiring that most foods, including dietary supplements, bear nutrition labeling. Subsequently, the Dietary Supplement Health and Education Act of 1994 (“DSHEA”)

---

=30&page=1; See also, HQ H295287 (June 18, 2020) available at <https://rulings.cbp.gov/search?term=HQ%20H295287&collection=ALL&sortBy=RELEVANCE&pageSize=30&page=1> (“CBP has a long-standing position that in order to be classified in Chapter 15, HTSUS, as fats or oils, products must predominantly be composed of triglycerides. See Headquarters Ruling Letter (“HQ”) H102457, dated September 8, 2010; HQ 963166, dated December 11, 2001; HQ 965396, dated July 23, 2002; HQ 964531, dated March 14, 2002; HQ 965699, dated September 25, 2002; New York Ruling Letter (“NY”) N234974, dated November 19, 2012.... Accordingly, only products composed primarily of triglycerides are classifiable under heading 1515, HTSUS.”); See, also, United States Pharmacopeia – National Formulary monograph catalog confirming different HTSUS as between fish oil and Omega-3 Fatty Acids.

1 amended the Act, in part, by defining "dietary supplements," adding specific labeling  
2 requirements for dietary supplements, and providing for optional labeling statements.

3 64. Dietary supplements must bear labeling in accordance with applicable  
4 provisions of FDCA. The IVC Product labels not only violate the clear mandates of  
5 the FDCA, but are independently false, misleading, and operate as a deception on the  
6 consuming public.

7 (1) *Fish Oil is not the Common or Usual Name of these*  
8 *Products*

9 65. The principal display panel ("PDP") of the IVC Product describes the  
10 supplement as "Triple Strength Fish Oil" containing "1000 mg of EPA/DHA Omega-  
11 3s.

12  
13 **Section 21 C.F.R. 101.3** states in relevant part:

14  
15 (a) The principal display panel of a food in package form shall bear as  
16 one of its principal features a statement of the identity of the commodity.


17 (b) Such statement of identity shall be in terms of: (1) The name now or  
18 hereafter specified in or required by any applicable Federal law or  
19 regulation; or, in the absence thereof, (2) The common or usual name of  
20 the food; or, in the absence thereof (3) An appropriately descriptive term,  
or when the nature of the food is obvious, a fanciful name commonly  
used by the public for such food.

21 66. The statement of identity for a dietary supplement is the name that  
22 appears on the label of the dietary supplement. As a general matter, the statement of  
23 identity of a dietary supplement is the name specified by federal law or regulation, or,  
24 if no such name is specified, its common or usual name. If the dietary supplement has  
25 no common or usual name and its nature is not obvious, the statement of identity must  
26 be an appropriately descriptive term.<sup>44</sup>

27  
28 <sup>44</sup> See, 21 U.S.C. 321(ff)(2)(C), 21 U.S.C. 343(s)(2)(B), 21 CFR §101.1 and 21 CFR §101.3; FDA  
Dietary Supplement Labeling Guide "FDA Labeling Guide") available at







71. Supplement manufacturers are generally required to disclose all ingredients contained in their products. 21 C.F.R. §101.36. The obligation to describe those ingredients by their common or usual name applies with same force in the Supplement Fact section as it does on the principal display panel. As detailed above, the common or usual name of the contents of these Products is Omega-3 fatty acid ethyl esters. The Supplement Facts also erroneously claim the Product contains EPA and DHA, which it does not. As detailed above, this Product contains 0 mg of Eicosapentaenoic acid (EPA) and 0 mg Docosahexaenoic acid (DHA). Once trans-esterified, the EPA in fish was substantively modified into ethyl icosapentate (aka Eicosapentaenoic acid ethyl ester) (EPA-EE) a molecule separate and distinct from EPA. Similarly, the Docosahexaenoic acid (DHA) in fish oil, once trans-esterified,



1 was substantively modified into ethyl docosahexaenate (aka Docosahexaenoic acid  
 2 ethyl ester) (DHA-EE), a molecule sperate and distinct from DHA. Although both  
 3 DHA-and DHA-EE may be listed by any number of synonyms, critically, none of  
 4 their synonyms are shared. Failure to properly identify EPA-EE and DHA-EE as  
 5 constituent ingredients violates the mandates of the FDCA and independently renders  
 6 the Products' Supplement Fact section false and misleading under state consumer  
 7 protection laws.

8 72. As detailed above, trans-esterification substantially transformed "fish oil"  
 9 into an Omega-3 acid ethyl ester. This transformation also affected all the individual  
 10 components of the fish oil either by eliminating them entirely, or transforming them  
 11 into fatty acid ethyl esters. Each of these omegas, although once triglycerides are now  
 12 ethyl esters, different molecules with different common and usual names.

### 13 (3) *IVC Fails to List All the Ingredients in the Products*

14 73. While the Product principally contains EPA-EE and DHA-EE, it also  
 15 contains 65 mg of other omega-3s which IVC fails to identify and list in the  
 16 Supplement Fact Sections in contravention of its obligations under the FDCA.

17 74. Section 21 C.F.R. §101.36 applies specifically to the nutrition labeling of  
 18 dietary supplements. It divides dietary ingredients into two categories – those that  
 19 have a Reference Daily Intake (RDI) or a Daily Reference Value (DRV) as  
 20 established in §101.9(c) (referred to as "(b)(2)-dietary ingredients") and those that do  
 21 not have an RDI/DRV (referred as "other ingredients"). 21 CFR §§101.36(b)(2) and  
 22 (3).

23 75. Dietary ingredients for which no daily values have been established must  
 24 be listed by their common or usual names when they are present in a dietary  
 25 supplement. They must be identified as having no Daily Values by use of a symbol in  
 26 the column for % Daily Value that refers to the footnote Daily Value Not Established.  
 27 21 CFR 101.36(b)(2)(iii)(F) and (b)(3).

1 76. OM3s, in any form, do not have an RDI/DVR and therefore are  
 2 considered other dietary ingredients. Their constituent components must be listed  
 3 pursuant to 21 C.F.R. §101.36(b)(3).

4 77. IVC's failure to include these sub-components in the Supplement Fact  
 5 Section further deprives consumers of material information relevant to making  
 6 informed purchasing decisions. Failure to include this information operates as a fraud  
 7 and deception on the consuming public and is violation of the law.

#### 8 (4) *Other Labeling Misrepresentations*

9 78. The FDCA deems dietary supplements to be misbranded if their labeling  
 10 is false or misleading in any way. 21 U.S.C. § 343.

11 79. In addition to the above, the PDP claims it is "Triple Strength." While  
 12 comparative nutrient content claims are generally allowed, they require notice of the  
 13 comparable product. Here, IVC not only fails to identify such a product, even if one  
 14 were to assume the comparator is a standard 1000 mg fish oil capsule, such a  
 15 representation would also be false and misleading as IVC's Product contains 0 mg of  
 16 EPA and 0 mg of DHA and it's not fish oil.

### 18 **ECONOMIC INJURY**

19 80. Plaintiff sought to buy products that were lawfully labeled, marketed and  
 20 sold.

21 81. Plaintiff saw and relied on Defendants' misleading labeling of their  
 22 Products.

23 82. Plaintiff believed that the Product purchased contained real fish oil.

24 83. Plaintiff believed that the Product was lawfully marketed and sold.

25 84. In reliance on the claims made by Defendants regarding the qualities of  
 26 their Product, Plaintiff paid for a Product which he did not receive and/or paid a price  
 27 premium.



1           93. Plaintiff brings this Class pursuant to Federal Rule of Civil Procedure  
2 23(a), and 23(b)(1), 23(b)(2), 23(b)(3) and 23(c)(4).

3           94. Excluded from the Classes are: (i) Defendants and their employees,  
4 principals, affiliated entities, legal representatives, successors and assigns; and (ii) the  
5 judges to whom this action is assigned.

6           95. Upon information and belief, there are tens of thousands of members of  
7 the Class. Therefore, individual joinder of all members of the Class would be  
8 impracticable.

9           96. There is a well-defined community of interest in the questions of law and  
10 fact affecting the parties represented in this action.

11           97. Common questions of law or fact exist as to all members of the Class.  
12 These questions predominate over the questions affecting only individual Class  
13 members. These common legal or factual questions include but are not limited to:

- 14           a. Whether Defendants marketed, packaged, or sold the Class  
15           Products to Plaintiff and those similarly situated using false,  
16           misleading, or deceptive statements or representations;
- 17           b. Whether Defendants omitted or misrepresented material facts  
18           in connection with the sales of their Products;
- 19           c. Whether Defendants participated in and pursued the common  
20           course of conduct complained of herein;
- 21           d. Whether Defendants have been unjustly enriched as a result  
22           of their unlawful business practices;
- 23           e. Whether Defendant's actions violate the Unfair Competition  
24           Law, Cal. Bus. & Prof. Code §§17200, *et seq.* (the "UCL");
- 25           f. Whether Defendant's actions violate the False Advertising  
26           Law, Cal. Bus. & Prof. Code §§17500, *et seq.* (the "FAL");
- 27           g. Whether Defendant's actions violate the Consumers Legal  
28           Remedies Act, Cal. Civ. Code §§1750, *et seq.* (the "CLRA");

- h. Whether Defendants' actions violate the N.Y. Gen. Bus. Laws § 349, *et. seq.*;
- i. Whether Defendants' actions violate N.Y. Gen. Bus. Laws § 350 *et. seq.*;
- j. Whether Defendants' actions constitute breach of express warranty;
- k. Whether Defendants should be enjoined from continuing the above-described practices;
- l. Whether Plaintiff and members of the Class are entitled to declaratory relief; and
- m. Whether Defendants should be required to make restitution, disgorge profits, reimburse losses, and pay damages as a result of the above-described practices.

98. Plaintiff's claims are typical of the claims of the Class, in that Plaintiff was a consumer who purchased Defendants' Product. Plaintiff is no different in any relevant respect from any other Class member who purchased the Product, and the relief sought is common to the Class.

99. Plaintiff is an adequate representative of the Class because his interests do not conflict with the interests of the members of the Class he seeks to represent, and he has retained counsel competent and experienced in conducting complex class action litigation. Plaintiff and his counsel will adequately protect the interests of the Class.

100. A class action is superior to other available means for the fair and efficient adjudication of this dispute. The damages suffered by each individual Class member likely will be relatively small, especially given the cost of the Products at issue and the burden and expense of individual prosecution of the complex litigation necessitated by Defendants' conduct. Thus, it would be virtually impossible for members of the Class individually to effectively redress the wrongs done to them.

Moreover, even if members of the Class could afford individual actions, it would still not be preferable to class-wide litigation. Individualized actions present the potential for inconsistent or contradictory judgments. By contrast, a class action presents far fewer management difficulties and provides the benefits of single adjudication, economies of scale, and comprehensive supervision by a single court.

101. In the alternative, the Class may be certified because Defendants have acted or refused to act on grounds generally applicable to the Class, thereby making appropriate preliminary and final equitable relief with respect to each Class.

102. The requirements for maintaining a class action pursuant to Rule 23(b)(2) are also met, as Defendants have acted or refused to act on grounds generally applicable to the Class, thereby making appropriate final injunctive relief or corresponding declaratory relief with respect to the Class as a whole.

### **FIRST CAUSE OF ACTION**

#### **Unlawful Business Practices Violation of The Unfair Competition Law (“UCL”) Bus. & Prof. Code §§17200, *et seq.***

103. Plaintiff incorporates each and every allegation contained in the paragraphs above as if restated herein.

104. The UCL defines unfair business competition to include any “unlawful, unfair or fraudulent” act or practice, as well as any “unfair, deceptive, untrue or misleading” advertising. Cal. Bus. Prof. Code §17200.

105. A business act or practice is “unlawful” if it violates any established state or federal law.

106. Defendants’ acts, omissions, misrepresentations, practices, and/or non-disclosures concerning the Products alleged herein, constitute “unlawful” business acts and practices in that they violate the Federal Food, Drug, and Cosmetic Act, 21



1 U.S.C. §§301, et seq. and its implementing regulations, including, at least, the  
 2 following sections:

- 3 a. 21 U.S.C. §343(a), which deems food misbranded when its  
 4 labeling contains a statement that is false or misleading in any  
 5 particular;
- 6 b. 21 C.F.R. §102.5(a)-(d), which prohibits the naming of foods so as  
 7 to create an erroneous impression about the presence or absence of  
 8 ingredient(s) or component(s) therein;
- 9 c. 21 U.S.C. §§331 and 333, which prohibits the introduction of  
 10 misbranded foods into interstate commerce.
- 11 d. 21 C.F.R. §101.3 and 21 C.F.R. §101.36 as described above,  
 12 pertaining to, *inter alia*, use of common or usual names.

13 107. California has expressly adopted federal labeling requirements as its own  
 14 pursuant to the Sherman Food, Drug, and Cosmetic Law, CAL. HEALTH & SAFETY  
 15 CODE § 109875 et seq. (the “Sherman Law”), the Sherman Law, which provides that  
 16 “[a]ll food labeling regulations and any amendments to those regulations adopted  
 17 pursuant to the federal act, in effect on January 1, 1993, or adopted on or after that  
 18 date shall be the food regulations of this state.” CAL. HEALTH & SAFETY CODE §  
 19 110100.

20 108. Each of IVC’s violations of federal law and regulations violates  
 21 California’s Sherman Food, Drug, and Cosmetic Law, CAL. HEALTH & SAFETY  
 22 CODE § 109875 et seq. (the “Sherman Law”), including, but not limited to, the  
 23 following sections:

24 109. Section 110100 (adopting all FDA regulations as state regulations);

25 110. Section 110290 (“In determining whether the labeling or advertisement  
 26 of a food . . . is misleading, all representations made or suggested by statement, word,  
 27 design, device, sound, or any combination of these, shall be taken into account.”);

1           111. Section 110390 (“It is unlawful for any person to disseminate any false  
2 advertisement of any food. . . . An advertisement is false if it is false or misleading in  
3 any particular.”);

4           112. Section 110395 (“It is unlawful for any person to manufacture, sell,  
5 deliver, hold, or offer for sale any food . . . that is falsely advertised.”);

6           113. Section 110398 (“It is unlawful for any person to advertise any food,  
7 drug, device, or cosmetic that is adulterated or misbranded.”);

8           114. Section 110400 (“It is unlawful for any person to receive in commerce  
9 any food . . . that is falsely advertised or to deliver or proffer for delivery any such  
10 food . . . .”); and

11           115. Section 110660 (“Any food is misbranded if its labeling is false or  
12 misleading in any particular.”).

13           116. Each of the challenged omissions, statements, and actions by IVC  
14 violates the FDCA, and the Sherman Law, and, consequently, violates the “unlawful”  
15 prong of the UCL.

16           117. IVC’s conduct is further “unlawful” because it violates California’s False  
17 Advertising Law, CAL. BUS. & PROF. CODE § 17500 et seq. (the “FAL”), and  
18 California’s Consumers Legal Remedies Act, CAL. CIV. CODE § 1750 et seq. (the  
19 “CLRA”), as discussed in the claims below.

20           118. By committing the unlawful acts and practices alleged above, Defendants  
21 have engaged, and continue to be engaged, in unlawful business practices within the  
22 meaning of California Business and Professions Code §§17200, *et seq.*

23           119. Through their unlawful acts and practices, Defendants have obtained, and  
24 continues to unfairly obtain, money from members of the Class. As such, Plaintiff  
25 requests that this Court cause Defendants to restore this money to Plaintiff and all  
26 members of the Class, to disgorge the profits Defendants made on these transactions,  
27 and to enjoin Defendants from continuing to violate the Unfair Competition Law or  
28

1 violating it in the same fashion in the future. Otherwise, the Class may be irreparably  
 2 harmed and denied an effective and complete remedy if such an order is not granted.

## 3 4 **SECOND CAUSE OF ACTION**

### 5 **Unfair Business Practices** 6 **Violation of The Unfair Competition Law** 7 **Bus. & Prof. Code §§ 17200, *et seq.***

8 120. Plaintiff incorporates each and every allegation contained in the  
 9 paragraphs above as if restated herein.

10 121. The UCL defines unfair business competition to include any “unlawful,  
 11 unfair or fraudulent” act or practice, as well as any “unfair, deceptive, untrue or  
 12 misleading” advertising. Cal. Bus. Prof. Code §17200.

13 122. A business act or practice is “unfair” under the Unfair Competition Law if  
 14 the reasons, justifications and motives of the alleged wrongdoer are outweighed by the  
 15 gravity of the harm to the alleged victims.

16 123. Defendants have violated, and continue to violate, the “unfair” prong of  
 17 the UCL through their misleading description of the Products. The gravity of the harm  
 18 to members of the Class resulting from such unfair acts and practices outweighs any  
 19 conceivable reasons, justifications, or motives of Defendants for engaging in such  
 20 deceptive acts and practices. By committing the acts and practices alleged above,  
 21 Defendants engaged, and continued to engage, in unfair business practices within the  
 22 meaning of California Business and Professions Code §§17200, *et seq.*

23 124. Through their unfair acts and practices, Defendants obtained, and  
 24 continued to unfairly obtain, money from members of the Class. As such, Plaintiff has  
 25 been injured and requests that this Court cause Defendants to restore this money to  
 26 Plaintiff and the members of the Class, to disgorge the profits Defendants made on their  
 27 Products, and to enjoin Defendants from continuing to violate the Unfair Competition  
 28 Law or violating it in the same fashion in the future. Otherwise, the Class may be

1 irreparably harmed and denied an effective and complete remedy if such an Order is not  
2 granted.

3 **THIRD CAUSE OF ACTION**  
4 **Fraudulent Business Practices**  
5 **Violation of The Unfair Competition Law**  
6 **Bus. & Prof. Code §§ 17200, *et seq.***

7 125. Plaintiff incorporates each and every allegation contained in the  
8 paragraphs above as if restated herein.

9 126. The UCL defines unfair business competition to include any “unlawful,  
10 unfair or fraudulent” act or practice, as well as any “unfair, deceptive, untrue or  
11 misleading” advertising. Cal. Bus. & Prof. Code §17200.

12 127. A business act or practice is “fraudulent” under the Unfair Competition  
13 Law if it actually deceives or is likely to deceive members of the consuming public.

14 128. Defendants’ acts and practices of mislabeling their Products in a manner  
15 to suggest they principally contained their characterizing ingredients.

16 129. As a result of the conduct described above, Defendants have been, and  
17 will continue to be, unjustly enriched at the expense of Plaintiff and members of the  
18 proposed Class. Specifically, Defendants have been unjustly enriched by the profits  
19 they have obtained from Plaintiff and the Class from the purchases of their Products.

20 130. Through their fraudulent acts and practices, Defendants have improperly  
21 obtained, and continue to improperly obtain, money from members of the Class. As  
22 such, Plaintiff requests that this Court cause Defendants to restore this money to  
23 Plaintiff and the Class, to disgorge the profits Defendants have made, and to enjoin  
24 Defendants from continuing to violate the Unfair Competition Law or violating it in  
25 the same fashion in the future. Otherwise, the Class may be irreparably harmed and  
26 denied an effective and complete remedy if such an Order is not granted.  
27  
28

**FOURTH CAUSE OF ACTION**

**False Advertising**

**Violation of California Business & Professions Code §§ 17500, *et seq.***

131. Plaintiff incorporates each and every allegation contained in the paragraphs above as if restated herein.

132. Defendants use advertising and packaging to sell its Products. Defendants disseminate advertising regarding their Products which by their very nature are deceptive, untrue, or misleading within the meaning of California Business & Professions Code §§17500, *et seq.* because those advertising statements contained on the labels are misleading and likely to deceive, and continue to deceive, members of the putative Class and the general public.

133. In making and disseminating the statements alleged herein, Defendants knew or should have known that the statements were untrue or misleading, and acted in violation of California Business & Professions Code §§17500, *et seq.*

134. The misrepresentations and non-disclosures by Defendants of the material facts detailed above constitute false and misleading advertising and therefore constitute a violation of California Business & Professions Code §§17500, *et seq.*

135. Through their deceptive acts and practices, Defendants have improperly and illegally obtained money from Plaintiff and the members of the Class. As such, Plaintiff requests that this Court cause Defendants to restore this money to Plaintiff and the members of the Class, and to enjoin Defendants from continuing to violate California Business & Professions Code §§17500, *et seq.*, as discussed above. Otherwise, Plaintiff and those similarly situated will continue to be harmed by Defendant's false and/or misleading advertising.

136. Pursuant to California Business & Professions Code §17535, Plaintiff seeks an Order of this Court ordering Defendants to fully disclose the true nature of their misrepresentations. Plaintiff additionally requests an Order: (1) requiring Defendants to disgorge its ill-gotten gains, (2) award full restitution of all monies

1 wrongfully acquired by Defendants and (3), interest and attorneys' fees. Plaintiff and  
2 the Class may be irreparably harmed and denied an effective and complete remedy if  
3 such an Order is not granted.

4  
5 **FIFTH CAUSE OF ACTION**  
6 **Violation of the Consumers Legal Remedies Act**  
7 **California Civil Code §§ 1750, *et seq.***

8 137. Plaintiff incorporates each and every allegation contained in the  
9 paragraphs above as if restated herein.

10 138. This cause of action is brought pursuant to the Consumers Legal  
11 Remedies Act, California Civil Code §§1750, *et seq.* (the "CLRA").

12 139. Plaintiff and each member of the proposed Class are "consumers" within  
13 the meaning of Civil Code §1761(d).

14 140. The purchases of the Products by consumers constitute "transactions"  
15 within the meaning of Civil Code §1761(e) and the Products constitute "goods" within  
16 the meaning of Civil Code §1761(a).

17 141. Defendants have violated, and continue to violate, the CLRA in at least  
18 the following respects:

- 19 a. §1770(5) pertaining to misrepresentations regarding the  
20 characteristics of goods sold—specifying that misleading  
21 representations regarding ingredients violate the CLRA;  
22 b. §1770(7) pertaining to misrepresentations regarding the standard,  
23 quality, or grade of goods sold; and  
24 c. § 1770(9) pertaining to goods advertised with the intent not to  
25 provide what is advertised.

26 142. Defendants knew, or should have known, that the labeling of their  
27 Products violated consumer protection laws, and that these statements would be relied  
28 upon by Plaintiff and the members of the Class.



1           143. The representations were made to Plaintiff and all members of the Class.  
2 Plaintiff relied on the accuracy of the representations on Defendants' labels which  
3 formed a material basis for his decision to purchase the Products. Moreover, based on  
4 the very materiality of Defendants' misrepresentations uniformly made on or omitted  
5 from their Product labels, reliance may be presumed or inferred for all members of the  
6 Class.

7           144. Defendant carried out the scheme set forth in this Complaint willfully,  
8 wantonly, and with reckless disregard for the interests of Plaintiff and the Class, and  
9 as a result, Plaintiff and the Class have suffered an ascertainable loss of money or  
10 property.

11           145. Plaintiff and the members of the Class request that this Court enjoin  
12 Defendants from continuing to engage in the unlawful and deceptive methods, acts  
13 and practices alleged above, pursuant to California Civil Code §1780(a)(2). Unless  
14 Defendants are permanently enjoined from continuing to engage in such violations of  
15 the CLRA, future consumers of Defendants' Products will be damaged by their acts  
16 and practices in the same way as have Plaintiff and the members of the proposed  
17 Class.

18           146. In conjunction with the Complaint, Plaintiff will serve a CLRA demand  
19 pursuant to Civil Code §1782, notifying Defendant of the conduct described herein  
20 and that such conduct was in violation of particular provisions of Civil Code §1770.  
21 Absent a proper remedy, Plaintiff will amend his complaint to seek damages pursuant  
22 to Civil Code § 1780(a).

23  
24  
25  
26  
27  
28

**SIXTH CAUSE OF ACTION**  
**Breach of Express Warranty**  
**On Behalf of the New York Sub Class**

147. Plaintiff incorporates each and every allegation contained in the paragraphs above as if rewritten herein.

148. Plaintiff's express warranty claims are based on violations of N.Y. CLS UCC § 2-313 and § 2-607. Defendants were afforded reasonable notice of this claim in advance of the filing of this complaint.

149. Defendant made express warranties to Plaintiff and members of the Class that the Products they purchased consisted of real fish oil in its triglyceride form; that its constituent components were DHA and EPA (as opposed to DHA-EE and EPA-EE).

150. The express warranties made to Plaintiff and members of the Class appear on every Product label. This warranty regarding the nature of the Product marketed by Defendant specifically relates to the goods being purchased and became the basis of the bargain.

151. Plaintiff and the Class purchased the Products in the belief that they conformed to the express warranties that were made on the Products' labels.

152. Defendant breached the express warranties made to Plaintiff and members of the Class by failing to supply goods that conformed to the warranties it made. As a result, Plaintiff and members of the Class suffered injury and deserve to be compensated for the damages they suffered.

153. Plaintiff and the members of the Class paid money for the Products. However, Plaintiff and the members of the Class did not obtain the full value of the advertised Products. If Plaintiff and other members of the Class had known of the true nature of the Products, they would not have purchased them or paid less for them. Accordingly, Plaintiff and members of the Class have suffered injury in fact and lost money or property as a result of Defendants' wrongful conduct.

1 154. Plaintiff and the Class are therefore entitled to recover damages, punitive  
2 damages, equitable relief such as restitution and disgorgement of profits, and  
3 declaratory and injunctive relief.

4  
5 **SEVENTH CAUSE OF ACTION**  
6 **VIOLATION OF N.Y. GEN. BUS. LAW § 349, *Et Seq.***  
7 **On Behalf of the New York Subclass**

8 155. Plaintiff incorporates each and every allegation contained in the  
9 paragraphs above as if rewritten herein.

10 156. Plaintiff brings this claim on behalf of the New York Class for violation  
11 of New York's Consumer Protection from Deceptive Acts and Practices Law, N.Y.  
12 GEN. BUS. LAW § 349 et seq.

13 157. New York General Business Law Section 349 ("GBL § 349") declares  
14 unlawful "[deceptive acts or practices in the conduct of any business, trade, or  
15 commerce or in the furnishing of any service in this state ... "

16 158. Defendants' labeling and marketing of the Product, as alleged herein,  
17 constitutes "deceptive" acts and practices within the meaning of GBL §349.

18 159. Plaintiff and Class Members have been injured inasmuch as they paid for  
19 and/or paid a premium for a Product that, contrary to its label, was not fish oil and did  
20 not contain its claimed amount of DHA and EPA.

21 160. GBL § 349(h) provides in relevant part that "any person who has been  
22 injured by reason of any violation of [GBL § 349] may bring an action in his own  
23 name to enjoin such unlawful act or practice, an action to recover his actual damages  
24 or fifty dollars, whichever is greater, or both such actions. The court may, in its  
25 discretion, increase the award of damages to an amount not to exceed three times the  
26 actual damages up to one thousand dollars, if the court finds the defendant willfully or  
27 knowingly violated this section. The court may award reasonable attorney's fees to a  
28 prevailing plaintiff.

1 161. In accordance with §349(h), Plaintiff seeks an order enjoining  
2 Defendants from continuing the unlawful deceptive acts and practices set forth above.

3 162. Absent a Court order enjoining the unlawful deceptive acts and practices,  
4 Defendants will continue their false and misleading marketing campaign and, in doing  
5 so, irreparably harm each member of the Class.

6 163. As a consequence of Defendants' deceptive acts and practices, Plaintiff  
7 and other members of the Class suffered an ascertainable loss of monies. By reason of  
8 the foregoing, Plaintiff and other members of the Class seek actual damages or  
9 statutory damages of \$50 per violation, whichever is greater, as well as punitive  
10 damages. N.Y. GEN. BUS. LAW § 349(h).

11  
12 **EIGHTH CAUSE OF ACTION**  
13 **N.Y. GEN. BUS. LAW § 350, *Et Seq.***  
14 **On Behalf of the New York Subclass**

15 164. Plaintiff incorporates each and every allegation contained in the  
16 paragraphs above as if rewritten herein.

17 165. N.Y. Gen. Bus. Law § 350 declares false advertising in the conduct of  
18 any business, trade or commerce or in the furnishing of any service in this state to be  
19 unlawful. The term 'false advertising' means advertising, including labeling, of a  
20 commodity, or of the kind, character, terms or conditions of any employment  
21 opportunity if such advertising is misleading in a material respect. In determining  
22 whether any advertising is misleading, there shall be taken into account (among other  
23 things) not only representations made by statement, word, design, device, sound or  
24 any combination thereof, but also the extent to which the advertising fails to reveal  
25 facts material in the light of such representations with respect to the commodity or  
26 employment to which the advertising relates under the conditions proscribed in said  
27 advertisement, or under such conditions as are customary or usual. 91. N.Y. Gen.  
28 Bus. Law § 350-a(l).

1 166. Defendants' labeling and advertisements contain untrue and materially  
2 misleading statements regarding the contents of the Supplement.

3 167. Plaintiff and members of the Class have been injured inasmuch as they  
4 relied upon the labeling and advertising and paid a premium for a product that did not  
5 conform to its representations. Accordingly, Plaintiff and the Class Members  
6 received less than what they bargained and/or for which they paid a premium.

7 168. Defendants' advertising and product labeling induced the Plaintiff and  
8 Class Members to buy their Product.

9 169. Defendants knew, or by exercising reasonable care should have known,  
10 that their statements and representations as described in this Complaint were untrue  
11 and/or misleading.

12 170. Defendants made the material misrepresentations described in this  
13 Complaint on its Product labels.

14 171. As a result of Defendants' false or misleading labeling and advertising,  
15 Plaintiff and Class Members are entitled to monetary damages, statutory damages,  
16 injunctive relief, restitution, disgorgement of all monies obtained by means of IVC's  
17 unlawful conduct, interest, and attorneys' fees and costs.

18 **NINTH CAUSE OF ACTION**

19 **Restitution Based On Quasi-Contract/Unjust Enrichment**

20 172. Plaintiff incorporates each and every allegation contained in the  
21 paragraphs above as if rewritten herein.

22 173. Defendants' conduct in enticing Plaintiff and the Class to purchase their  
23 Products with false and misleading packaging is unlawful because the statements  
24 contained on the Defendants' Product labels are untrue.

25 174. Defendants took monies from Plaintiff and the Class for these Products  
26 and have been unjustly enriched at the expense of Plaintiff and the Class as result of  
27 their unlawful conduct alleged herein, thereby creating a quasi-contractual obligation  
28

1 on Defendants to restore these ill-gotten gains to Plaintiff and the Class. It is against  
2 equity and good conscience to permit Defendants to retain the ill-gotten benefits  
3 received from Plaintiff and Class members.

4 175. As a direct and proximate result of Defendants' unjust enrichment,  
5 Plaintiff and the Class are entitled to restitution or restitutionary disgorgement in an  
6 amount to be proved at trial.

7  
8 **PRAYER FOR RELIEF**

9 THEREFORE, Plaintiff, on behalf of himself and on behalf of the other  
10 members of the Class and for the Counts so applicable on behalf of the general public  
11 request an award and relief as follows:

12 A. An order certifying that this action is properly brought and may be  
13 maintained as a class action, that Plaintiff be appointed Class Representative, and  
14 Plaintiff's counsel be appointed Lead Counsel for the Class.

15 B. Restitution in such amount that Plaintiff and all members of the Class  
16 paid to purchase Defendants' Product or restitutionary disgorgement of the profits  
17 Defendant obtained from those transactions, for Causes of Action for which they are  
18 available.

19 C. Compensatory damages for Causes of Action for which they are  
20 available.

21 D. Statutory penalties for Causes of Action for which they are available.

22 E. Punitive Damages for Causes of Action for which they are available.

23 F. A declaration and Order enjoining Defendant from marketing and  
24 labeling their Products deceptively, in violation of laws and regulations as specified in  
25 this Complaint.

26 G. An Order awarding Plaintiff his costs of suit, including reasonable  
27 attorneys' fees and pre and post judgment interest.



1 H. An Order requiring an accounting for, and imposition of, a constructive  
2 trust upon all monies received by Defendant as a result of the unfair, misleading,  
3 fraudulent and unlawful conduct alleged herein.

4 I. Such other and further relief as may be deemed necessary or appropriate.

5 **DEMAND FOR JURY TRIAL**

6 Plaintiff hereby demands a trial by jury on all causes of action or issues so triable.  
7

8  
9 DATED: May 13, 2021

Respectfully submitted,

10  
11   
12

13 Michael D. Braun  
14 **KUZYK LAW, LLP**  
15 1999 Avenue of the Stars, Ste. 1100  
16 Los Angeles, California 90067  
17 Telephone: (213) 401-4100  
Facsimile: (213) 401-0311  
Email: mdb@kuzykclassactions.com

18  
19 **KAPLAN FOX & KILSHEIMER LLP**  
20 Laurence D. King (SBN 206423)  
lking@kaplanfox.com  
21 Maia Kats (to be admitted pro hac vice)  
mkats@kaplanfox.com  
22 Mario M. Choi (SBN 243409)  
mchoi@kaplanfox.com  
23 1999 Harrison Street, Suite 1560  
Oakland, CA 94612  
24 Telephone: (415) 772-4700  
Facsimile: (415) 772-4707

25  
26 *Counsel for Plaintiff*  
27  
28